MYB33 Antibody

What is MYB33 and what is its structural relationship to other MYB family members?

MYB33 belongs to the R2R3 MYB domain family of transcription factors. In plants such as Arabidopsis, MYB33 is part of a distinct subclass of GAMYB-like genes that includes MYB33, MYB65, MYB97, MYB101, and MYB120, all of which are phylogenetically related to HvGAMYB . These proteins are characterized by:

• A conserved R2R3 DNA binding domain that recognizes specific DNA sequences

• A unique intron located at the 3′ end of the open reading frame, distinguishing them as a specific subclass within the MYB superfamily

• Functional conservation allowing some members (MYB33, MYB65, and MYB101) to substitute for HvGAMYB in transactivation assays

• A highly conserved microRNA (miRNA) target motif in their coding sequence that regulates their expression

In mammals, c-Myb is a related transcription factor that functions as a DNA-binding protein specifically recognizing the sequence 5'-YAAC[GT]G-3' and plays important roles in hematopoietic cell proliferation and differentiation .

What are the key biological functions of MYB33 in plant systems?

In Arabidopsis, MYB33 and its close homolog MYB65 function redundantly in several developmental processes:

• Anther development: Double mutants of MYB33 and MYB65 (myb33 myb65) exhibit male sterility, indicating their essential role in pollen development

• Developmental regulation: While single mutants of either MYB33 or MYB65 show no obvious phenotypes, the double mutant demonstrates that these genes have overlapping functions in reproductive development

• Gene expression analysis shows MYB33 is expressed in flowers (sepals, style, receptacle, anther filaments), shoot apices, and root tips, although post-transcriptional regulation restricts the protein to primarily function in anthers

Expression studies using promoter-GUS and translational fusion constructs reveal that microRNA regulation significantly restricts MYB33 protein expression to specific tissues, suggesting tight developmental control is necessary for proper plant growth .

How can I distinguish between MYB33 and other closely related MYB family proteins in my experiments?

Distinguishing between closely related MYB family members requires multiple complementary approaches:

• Antibody specificity validation:

  • When using commercial antibodies, perform Western blot analysis with recombinant proteins of multiple MYB family members to confirm specificity

  • Include appropriate positive controls (tissues known to express the target) and negative controls (tissues or knockout lines lacking the target)

• Molecular approaches:

  • RT-qPCR using primers that target unique regions outside the conserved MYB domain

  • For ChIP experiments, validate antibody specificity using cells expressing epitope-tagged versions of your MYB protein of interest, as demonstrated with FLAG-tagged c-Myb in MCF-7 cells

• Genetic approaches:

  • Use T-DNA insertion mutants or CRISPR-edited lines as negative controls

  • Complementation studies with specific MYB genes to verify function, as demonstrated with the molecular complementation of myb33 myb65 double mutants with a genomic MYB33 clone

What are the optimal conditions for using MYB33 antibodies in Western blot applications?

For optimal Western blot results with MYB33 antibodies, consider these research-validated protocols:

• Sample preparation:

  • Separate nuclear and cytoplasmic fractions as MYB proteins are predominantly nuclear

  • Nuclear isolation protocol: Disrupt cells in buffer containing 10 mM KCl, 1.5 mM MgCl₂, 10 mM HEPES (pH 7.9), with protease inhibitors; collect nuclei by centrifugation at 10,000 × g for 5 minutes

  • Nuclear lysis buffer: 50 mM Tris pH 8.0, 1% SDS, 10 mM EDTA, with protease inhibitors

• Western blot conditions:

  • For c-Myb antibodies (which may have cross-reactivity with MYB33): Use at 1/500 dilution

  • Expected molecular weight: ~72 kDa for c-Myb ; adjust accordingly for your specific MYB protein

  • Include appropriate positive controls (e.g., HUVEC cell lysate for c-Myb)

  • Include peptide competition controls to verify specificity

• Signal detection optimization:

  • Consider using enhanced chemiluminescence for sensitive detection

  • For quantitative analysis, include a loading control and normalize signal intensity

How can I design effective ChIP experiments to study MYB33 binding to target gene promoters?

Designing effective ChIP experiments for MYB33 requires careful consideration of several factors:

• Antibody selection and validation:

  • Use antibodies raised against unique regions of MYB33 to avoid cross-reactivity

  • Validate antibody specificity using transgenic lines expressing epitope-tagged MYB33 proteins

  • Consider using plants expressing fusion proteins (e.g., MYC-MS188) that complement the mutant phenotype

• Chromatin preparation protocol:

  • Crosslink with 1% formaldehyde for 10 minutes at room temperature

  • For optimal shearing, consider enzymatic digestion: 40 units of Micrococcal nuclease in 200 μl of 50 mM Tris pH 8.0 for 10 min at 37°C

  • Stop reaction with 10 mM EDTA and lyse nuclei in 1% SDS

• ChIP procedure:

  • Immunoprecipitate with specific antibodies (commercial or custom), including appropriate controls (non-immune serum, IgG)

  • Design primers spanning MYB binding sites in promoters of interest

  • For MYB factors, focus on regions containing the core AACC binding motif

  • Include control regions (coding regions, non-target genes like GAPDH) for normalization

• Data analysis:

  • Perform quantitative PCR to measure enrichment at target sites

  • Calculate fold enrichment compared to control regions and control antibodies

  • Consider ChIP-seq for genome-wide binding site identification

What approaches are most effective for studying MYB33 regulation by microRNAs?

To study microRNA regulation of MYB33, employ these research-validated approaches:

• Identification of microRNA-target interactions:

  • Computational prediction of miRNA target sites (Arabidopsis MYB33 is regulated by miR159a, b, and c)

  • 5' RACE analysis to identify miRNA-guided cleavage products (as demonstrated for MYB33 and MYB65)

  • Sequencing of cleavage products to map precise cleavage sites

• Validation of functional miRNA regulation:

  • Generate transgenic plants expressing MYB33 with mutated miRNA target sequences (mMYB33)

  • Compare phenotypes between plants expressing wild-type MYB33 and mMYB33

  • Analyze MYB33 protein expression patterns using translational GUS fusions with either wild-type or mutated miRNA target sequences

• Experimental setup for analyzing miRNA regulation:

  • Compare MYB33 expression in wild-type plants versus mutants defective in miRNA biogenesis (e.g., hua enhancer 1, hyponastic leaves 1)

  • Analyze plants overexpressing the regulating miRNA (e.g., miR159a)

  • Use Agrobacterium-mediated delivery systems to demonstrate miRNA-directed cleavage of MYB33 mRNA in planta

• Quantification methods:

  • RT-qPCR to measure steady-state MYB33 transcript levels in different genetic backgrounds

  • Western blot to assess protein levels

  • Histochemical analysis of reporter gene expression patterns

Advanced Research Questions about MYB33 Function

The functional redundancy between MYB33 and MYB65 in anther development is supported by multiple lines of evidence and can be explained through several mechanisms:

• Genetic evidence for redundancy:

  • Single mutants (myb33 or myb65) show no visible phenotype

  • Double mutants (myb33 myb65) exhibit male sterility

  • Molecular complementation with a genomic MYB33 clone fully restores fertility in myb33 myb65 double mutants

  • Creation of a second allelic combination (myb33 myb65-2) confirms the phenotype is due to disruption of these specific genes

• Shared expression patterns and regulation:

  • Both genes show identical expression patterns in flowers, shoot apices, and root tips

  • Both contain the conserved miRNA target sequence that restricts their expression

  • This suggests shared transcriptional and post-transcriptional regulatory mechanisms

• Cellular basis of the anther defect:

  • In myb33 myb65 double mutants, early anther development (up to stage 5) appears normal

  • Defects first appear at stage 6 when the tapetum begins to enlarge abnormally

  • Later stages show absence of tetrads (products of meiosis) that are visible in wild-type anthers

  • This suggests both genes function in the same developmental pathway regulating tapetum development and/or PMC meiosis

• Evolutionary basis for redundancy:

  • MYB33 and MYB65 likely arose through gene duplication

  • Both genes contain the unique 3' intron characteristic of GAMYB-like genes

  • Conservation of function suggests selective pressure to maintain redundancy for reproductive success

What are the target genes of MYB33 and how can they be systematically identified?

Identifying MYB33 target genes requires integrated approaches combining chromatin immunoprecipitation, expression analysis, and functional validation:

• ChIP-based identification of direct binding targets:

  • For MYB family proteins, design ChIP experiments focusing on regions containing the core binding motif AACC

  • MS188 (another MYB protein) has been shown to bind promoters of genes like PKSA, PKSB, and MS2 at sites containing this motif

  • For ChIP experiments, design multiple probes spanning potential binding sites as well as control regions (coding sequences)

• Integrated ChIP and expression analysis pipeline:

  • Perform ChIP-chip or ChIP-seq with specific MYB33 antibodies or epitope-tagged versions

  • Combine with RNA-seq comparing wild-type and myb33 myb65 mutants to identify genes with both binding evidence and expression changes

  • For quantitative validation, use RT-qPCR to verify expression changes in selected targets

• Validation of direct binding:

  • Perform electrophoretic mobility shift assays (EMSA) using recombinant MYB33 protein and labeled DNA fragments containing putative binding sites

  • Include competition assays with unlabeled probes (25-fold and 50-fold excess) to confirm binding specificity

  • Test binding to mutated binding sites as negative controls

• Functional validation of targets:

  • Analyze promoters of putative targets for enrichment of MYB binding motifs

  • Perform reporter gene assays with wild-type and mutated binding sites

  • Test if expression of key targets can rescue specific aspects of the myb33 myb65 phenotype

Based on studies with other MYB proteins, potential direct targets might include genes involved in:

• Tapetum development

• Pollen wall formation

• Sporopollenin biosynthesis (based on binding of the related MS188 to promoters of PKSA, PKSB, and MS2)

What are common issues when working with MYB33 antibodies and how can they be resolved?

When working with MYB33 antibodies, researchers may encounter several technical challenges that require systematic troubleshooting:

• Cross-reactivity with related MYB proteins:

  • Problem: MYB proteins share highly conserved DNA-binding domains

  • Solution: Perform peptide competition assays to verify specificity

  • Approach: Pre-incubate antibody with synthetic peptide corresponding to the immunogen before application to Western blot or immunostaining

  • Validation: Observe signal reduction or elimination with peptide competition, as demonstrated with c-Myb antibody ab117635

• Weak signal in immunodetection methods:

  • Problem: Low abundance of MYB transcription factors in many tissues

  • Solution: Optimize nuclear extraction and enrich for nuclear proteins

  • Protocol: Use nuclear/cytoplasmic fractionation with 10 mM KCl, 1.5 mM MgCl₂, 10 mM HEPES buffer followed by nuclear lysis in 50 mM Tris, 1% SDS, 10 mM EDTA

  • Alternative approach: Use epitope-tagged versions (FLAG, MYC) in transgenic lines or cell cultures for detection with high-affinity commercial tag antibodies

• Inconsistent ChIP results:

  • Problem: Variable enrichment of target regions

  • Solution: Optimize chromatin fragmentation and IP conditions

  • Approach: Consider enzymatic shearing (40 units Micrococcal nuclease for 10 min at 37°C) instead of sonication for more consistent fragment sizes

  • Controls: Include IgG control, input DNA, and non-target genomic regions (e.g., GAPDH) for normalization

• Difficulties detecting regulated protein expression:

  • Problem: miRNA regulation may result in low or tissue-specific protein expression

  • Solution: Use translational GUS fusions to visualize spatial expression patterns

  • Comparative approach: Create parallel constructs with wild-type and mutated miRNA target sequences to visualize the impact of post-transcriptional regulation

How can I interpret conflicting data between transcript levels and protein expression of MYB33?

Discrepancies between MYB33 transcript and protein levels are often observed due to post-transcriptional regulation. Here's how to interpret and investigate such conflicts:

• Recognizing microRNA-mediated regulation:

  • Observation: High transcript levels but low/undetectable protein expression

  • Interpretation: Suggests active miRNA-mediated regulation

  • Supporting evidence: Promoter-GUS fusions show broader expression than translational GUS fusions for MYB33

  • Validation approach: Compare wild-type MYB33 expression with constructs containing mutated miRNA target sequences

• Experimental approaches to resolve discrepancies:

  • Transcript analysis: Perform 5' RACE to detect miRNA-guided cleavage products

  • Protein stability: Conduct cycloheximide chase experiments to assess protein half-life

  • Tissue-specific regulation: Use cell-type specific promoters to express miRNA-resistant versions

  • Genetic background effects: Compare expression in wild-type plants versus mutants defective in miRNA biogenesis (e.g., hua enhancer 1, hyponastic leaves 1)

• Quantitative assessment of regulation:

  • Wild-type vs. miRNA mutants: Measure MYB33 transcript levels using RT-qPCR in plants with mutations affecting miRNA pathways

  • miRNA overexpression: Analyze MYB33 levels in plants overexpressing miR159a

  • Tissue-specific analysis: Microdissect specific tissues for more precise analysis of expression patterns

The following data illustrates how MYB33 expression can vary between transcript and protein levels:

How can ChIP-seq data for MYB33 be validated and integrated with other genomic datasets?

Validation and integration of MYB33 ChIP-seq data requires multiple complementary approaches:

• Technical validation of ChIP-seq peaks:

  • Local validation: Perform ChIP-qPCR on selected peaks and negative regions

  • Motif analysis: Confirm enrichment of MYB binding motifs (AACC core) in peak regions

  • Antibody validation: Compare results using different antibodies or epitope tags

  • Biological replicates: Ensure reproducibility across independent experiments

• Functional validation of binding sites:

  • EMSA confirmation: Test direct binding to peak sequences in vitro, including competition assays with unlabeled probes

  • Mutagenesis: Test the effect of mutating binding motifs on both binding (EMSA) and function (reporter assays)

  • Expression correlation: Compare binding with gene expression changes in myb33 myb65 mutants

• Integration with other genomic datasets:

  • RNA-seq: Correlate binding with differential expression between wild-type and mutants

  • Epigenomic data: Integrate with histone modification data (H3K27ac, H3K4me3) to identify active regulatory regions

  • Chromatin accessibility: Overlap with ATAC-seq or DNase-seq data to confirm binding at accessible regions

  • Other transcription factors: Compare with binding profiles of factors in the same regulatory pathways

• Advanced computational analyses:

  • De novo motif discovery: Identify potentially novel binding sequences beyond the canonical AACC motif

  • Pathway enrichment: Analyze whether target genes cluster in specific biological pathways

  • Binding site conservation: Compare binding site conservation across related species

How do plant MYB33 and mammalian c-Myb proteins differ in their molecular functions and research applications?

Plant MYB33 and mammalian c-Myb show both similarities and important differences in their molecular functions and experimental applications:

• Structural similarities and differences:

  • DNA binding domains: Both contain MYB DNA-binding domains that recognize similar core sequences (AACC/AACG)

  • Regulatory mechanisms: Plant MYB33 is regulated by microRNAs , while mammalian c-Myb is regulated primarily through protein-protein interactions and post-translational modifications

  • Domain organization: c-Myb contains transcriptional activation and negative regulatory domains , while plant MYB33 has distinct regulatory domains

• Biological functions:

  • Plant MYB33: Functions redundantly with MYB65 in anther development and male fertility

  • Mammalian c-Myb: Controls proliferation and differentiation of hematopoietic progenitor cells

  • Evolutionary relationship: Despite similar DNA-binding properties, they likely represent convergent evolution of transcription factor functions

• Experimental approaches and considerations:

  • Antibody applications: c-Myb antibodies are well-validated for Western blot (1/500 dilution), IHC-P, and ICC/IF

  • ChIP protocols: Both can be studied using ChIP, but optimal fixation and sonication conditions may differ between plant and animal tissues

  • Genetic manipulation: Plant systems offer T-DNA insertion mutants , while mammalian studies often use RNAi or CRISPR/Cas9

• Model systems and applications:

  • Plant research: Arabidopsis offers powerful genetics with double mutants showing clear phenotypes

  • Mammalian research: c-Myb studies focus on cancer biology and hematopoiesis, often using cell lines like MCF-7

  • Translational aspects: c-Myb research has direct medical implications for leukemia and breast cancer

Systematic analysis of MYB binding specificity provides crucial insights that can substantially improve experimental design for transcription factor studies:

• Refining ChIP experimental design:

  • Precise primer design: Target regions containing verified MYB binding motifs (AACC core)

  • Multiple probe approach: Design multiple probes spanning different motifs in target promoters

  • Control selection: Choose appropriate coding regions as negative controls

  • Peak prioritization: Focus validation on peaks containing enriched binding motifs

• Enhancing protein-DNA interaction assays:

  • EMSA optimization: Design oligonucleotides centered on core binding motifs

  • Competition assay design: Use 25-fold and 50-fold excess of unlabeled probes containing AACC motifs

  • Specificity controls: Include mutated binding sites as negative controls

  • Quantitative binding analysis: Perform saturation binding experiments to determine affinity constants

• Target gene prediction and validation:

  • Genome-wide motif scanning: Identify potential targets based on presence of validated binding sites

  • Integrative ranking: Prioritize genes with both binding sites and expression changes in mutants

  • Promoter-reporter assays: Test functionality of identified binding sites in vivo

  • Directed mutagenesis: Confirm the importance of specific nucleotides within the core motif

• Cross-species applications:

  • Conserved motif analysis: Compare MYB binding preferences across plant species

  • Evolutionary functional analysis: Test if MYB factors from different species can complement mutant phenotypes

  • Binding site conservation: Analyze whether binding sites are maintained in orthologous promoters

The following research pipeline illustrates how binding specificity analysis improves experimental design:

By incorporating detailed knowledge of MYB binding preferences into experimental design, researchers can achieve higher sensitivity, specificity, and biological relevance in their studies of transcription factor function.